ProShare Advisors LLC Has $827,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

ProShare Advisors LLC lifted its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 31.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 22,883 shares of the company's stock after purchasing an additional 5,503 shares during the quarter. ProShare Advisors LLC's holdings in SpringWorks Therapeutics were worth $827,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the company. Patient Square Capital LP acquired a new stake in SpringWorks Therapeutics during the 4th quarter valued at $3,365,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in SpringWorks Therapeutics by 2.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,013 shares of the company's stock worth $1,591,000 after acquiring an additional 931 shares in the last quarter. Integral Health Asset Management LLC purchased a new stake in SpringWorks Therapeutics in the 4th quarter worth about $3,613,000. Deutsche Bank AG lifted its stake in SpringWorks Therapeutics by 47.5% in the 4th quarter. Deutsche Bank AG now owns 60,714 shares of the company's stock worth $2,194,000 after acquiring an additional 19,540 shares in the last quarter. Finally, Duquesne Family Office LLC lifted its stake in SpringWorks Therapeutics by 21.9% in the 4th quarter. Duquesne Family Office LLC now owns 859,694 shares of the company's stock worth $31,061,000 after acquiring an additional 154,628 shares in the last quarter.

SpringWorks Therapeutics Stock Performance

Shares of NASDAQ SWTX traded up $0.24 during mid-day trading on Wednesday, reaching $46.70. 4,603,623 shares of the company traded hands, compared to its average volume of 2,190,212. The stock has a market cap of $3.52 billion, a PE ratio of -13.42 and a beta of 0.77. The company's fifty day moving average is $43.39 and its two-hundred day moving average is $42.94. SpringWorks Therapeutics, Inc. has a fifty-two week low of $28.21 and a fifty-two week high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). The company had revenue of $49.09 million for the quarter, compared to analyst estimates of $64.19 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. Research analysts forecast that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SWTX. Evercore ISI downgraded SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. Cowen lowered SpringWorks Therapeutics to a "hold" rating in a research report on Tuesday, April 29th. TD Cowen reaffirmed a "hold" rating and issued a $47.00 target price (down from $66.00) on shares of SpringWorks Therapeutics in a research report on Tuesday, April 29th. Barclays reaffirmed an "equal weight" rating and issued a $47.00 target price (down from $63.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. Finally, Guggenheim reaffirmed a "neutral" rating and issued a $47.00 target price on shares of SpringWorks Therapeutics in a research report on Monday, May 12th. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $52.57.

Insider Transactions at SpringWorks Therapeutics

In other news, CEO Saqib Islam sold 49,000 shares of SpringWorks Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $54.24, for a total transaction of $2,657,760.00. Following the sale, the chief executive officer now owns 954,869 shares of the company's stock, valued at approximately $51,792,094.56. This trade represents a 4.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Badreddin Edris sold 20,000 shares of SpringWorks Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $54.23, for a total value of $1,084,600.00. Following the sale, the chief operating officer now directly owns 169,712 shares in the company, valued at $9,203,481.76. The trade was a 10.54% decrease in their position. The disclosure for this sale can be found here. 7.83% of the stock is owned by insiders.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.